Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
What the trial team says
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Key facts
- Registry number
- NCT06116110
- Conditions studied
- Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma, Central Nervous System Lymphoma, Primary Mediastinal B-cell Lymphoma (PMBCL)
Where it is running
This trial lists 11 sites.
-
Arizona
- Banner MD Anderson Cancer Center (Gilbert)
-
California
- Stanford University (Stanford)
-
Connecticut
- Yale University (New Haven)
-
Illinois
- Robert H Lurie Cancer Center (Chicago)
-
Kansas
- University of Kansas Cancer Center (Westwood)
-
Maryland
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (Baltimore)
-
Massachusetts
- Dana Farber Cancer Institute (Boston)
-
North Carolina
- Duke University Medical Center - Division of Hematologic Malignancies (Durham)
-
Oregon
- Oregon Health and Science University Knight Cancer Institute (Portland)
-
Texas
- UT Southwestern Medical Center (Dallas)
-
Wisconsin
- Froedtert Hospital and the Medical College of Wisconsin (Milwaukee)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.